MKI67 and breast carcinoma: Although WOO studies do not have therapeutic intent, the potential clinical utility of Ki67 response to neoadjuvant endocrine therapy (fulvestrant, anastrozole, or both in combination) in patients with ER+ breast cancer is being investigated in the ALTERNATE (Alliance A011106; NCT01953588) trial [23–25].